XML 27 R37.htm IDEA: XBRL DOCUMENT v2.4.0.8
SEGMENT INFORMATION (Tables)
 3 Months Ended
Mar. 31, 2014
Segment Reporting [Abstract]  
Schedule of segment revenues and profit
Segment revenues and profit for the three-month periods ended March 31, 2014 and 2013 were as follows:
 
Three Months Ended
March 31,
 
2014
 
2013
Revenues:
 
 
 
Developed Markets(1)
$
1,421.8

 
$
780.3

Emerging Markets(2)
464.4

 
288.1

Total revenues
1,886.2

 
1,068.4

 
 
 
 
Segment profit:
 
 
 
Developed Markets(3)
439.3

 
187.7

Emerging Markets(4)
68.1

 
26.2

Total segment profit
507.4

 
213.9

 
 
 
 
Corporate(5)
(38.1
)
 
(37.7
)
Restructuring, integration and other costs
(133.6
)
 
(49.0
)
In-process research and development impairments and other charges
(12.0
)
 
—

Acquisition-related costs
(1.5
)
 
(7.9
)
Acquisition-related contingent consideration
(8.9
)
 
2.2

Other income (expense)
43.3

 
(4.5
)
Operating income
356.6

 
117.0

Interest income
1.8

 
1.6

Interest expense
(246.5
)
 
(155.3
)
Loss on extinguishment of debt
(93.7
)
 
(21.4
)
Foreign exchange and other
(13.4
)
 
1.4

Gain on investments, net
—

 
1.9

Income (loss) before provision for (recovery of) income taxes
$
4.8

 
$
(54.8
)
____________________________________
(1)
Developed Markets segment revenues reflect incremental product sales revenue of $665.1 million, in the aggregate, from all 2013 acquisitions and all 2014 acquisitions in the three-month period ended March 31, 2014, primarily from the B&L, Solta Medical and Obagi acquisitions.
(2)
Emerging Markets segment revenues reflect incremental product sales revenue of $216.4 million, in the aggregate, from all 2013 acquisitions and all 2014 acquisitions in the three-month period ended March 31, 2014, primarily from the B&L and Solta Medical acquisitions.
(3)
Developed Markets segment profit reflects the addition of operations from all 2013 acquisitions and all 2014 acquisitions, including the impact of acquisition accounting adjustments related to the fair value adjustments to inventory and identifiable intangible assets of $225.1 million, in the aggregate, in the three-month period ended March 31, 2014, primarily from B&L and Medicis operations.
(4)
Emerging Markets segment profit reflects the addition of operations from all 2013 acquisitions and all 2014 acquisitions, including the impact of acquisition accounting adjustments related to the fair value adjustments to inventory and identifiable intangible assets of $74.8 million, in the aggregate, in the three-month period ended March 31, 2014, primarily from B&L operations.
(5)
Corporate reflects non-restructuring-related share-based compensation expense of $15.2 million and $9.1 million in the three-month periods ended March 31, 2014 and 2013, respectively.
Schedule of total assets by segment
Total assets by segment as of March 31, 2014 and December 31, 2013 were as follows:
 
As of
March 31,
 2014
 
As of
December 31,
2013
Assets(1):
 
 
 
Developed Markets(2)
$
20,132.7

 
$
20,007.2

Emerging Markets(3)
6,936.2

 
6,907.8

 
27,068.9

 
26,915.0

Corporate
920.1

 
1,055.8

Total assets
$
27,989.0

 
$
27,970.8

____________________________________
(1)
The segment assets as of December 31, 2013 contain reclassifications between segments to conform to the current period presentation.
(2)
Developed Markets segment assets as of March 31, 2014 reflect the provisional amounts of identifiable intangible assets and goodwill of the Solta Medical acquisition of $99.2 million and $60.8 million, respectively.
(3)
Emerging Markets segment assets as of March 31, 2014 reflect the provisional amounts of identifiable intangible assets and goodwill of the Solta Medical acquisition of $66.6 million and $40.7 million, respectively.